Zydus working on single pen device for adjustable Semaglutide doses

Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It targets both diabetes and obesity. Clinical trials are underway in India. Zydus plans a day 1 launch in India. They will explore partnerships for emerging markets. The device aims to improve patient convenience. Some companies have shown interest in co-marketing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SK1XwPD
via IFTTT